NIR-PIT targeting CEA using chimeric anti-CEA mAb (Genara Biosciences LLC, Morgan Hill, CA, USA) or the anti-CEA IgG4 C2-45 suppressed tumor progression in gastric and pancreatic tumor models [35,112,113]. Here, CEACAM5 is linked to pancreatic neoplasm.